Early Career Scientists' (ECS) Contributions to Nanotechnology Applications in Bioengineering

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Nanotechnology Applications in Bioengineering".

Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 4832

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biotechnology and Biomedicine, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
Interests: applied micro and nanotechnology; food safety; molecular biology; pathogens; infectious diseases

E-Mail Website
Guest Editor
College of Pharmacy and Health Sciences, Butler University, Indianapolis, IN 46208, USA
Interests: nanomedicine; biomaterials and bioengineering; targeted delivery of anticancer drugs; non-viral gene delivery; 3D cell culture; microfluidics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to examine the scientific contribution of early career researchers exploring all interdisciplinary aspects of nanotechnology applications in bioengineering.

Each manuscript will be peer-reviewed with at least two referees in accordance with the peer review policy of the journal. Manuscripts are reviewed as quickly as possible with an editorial decision usually reached within three to four weeks following submission.

As this Special Issue is dedicated to researchers at the beginning of their academic career, it aims to make the publication process as transparent as possible and to give additional guidance on how to address reviewers’ comments. Nonetheless, the research will be assessed as rigorously as any other paper submitted to Bioengineering.

Prof. Dr. Dang Duong Bang
Prof. Dr. Sudip K. Das
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 4767 KiB  
Article
Isoliquiritigenin Nanoemulsion Preparation by Combined Sonication and Phase-Inversion Composition Method: In Vitro Anticancer Activities
by Jianman Wang, Hongjin Chen, Tao Guo, Ping Yue, Tianbao Qian, Xiangyu Zeng, Yali Luo, Jiangmin Li, Lijing Teng, Qingyu Liu, Liang Hong, Zijiang Yu and Zuquan Hu
Bioengineering 2022, 9(8), 382; https://doi.org/10.3390/bioengineering9080382 - 10 Aug 2022
Cited by 5 | Viewed by 1726
Abstract
Isoliquiritigenin (ILQ) has a number of biological activities such as antitumor and anti-inflammatory effects. However, biomedical applications of ILQ are impeded by its poor aqueous solubility. Therefore, in this research, we prepared a novel ILQ-loaded nanoemulsion, i.e., ILQ-NE, which consisted of Labrafil® [...] Read more.
Isoliquiritigenin (ILQ) has a number of biological activities such as antitumor and anti-inflammatory effects. However, biomedical applications of ILQ are impeded by its poor aqueous solubility. Therefore, in this research, we prepared a novel ILQ-loaded nanoemulsion, i.e., ILQ-NE, which consisted of Labrafil® M 1944 CS (oil), Cremophor® EL (surfactant), ILQ, and phosphate-buffered saline, by employing a combined sonication (high-energy) and phase-inversion composition (low-energy) method (denoted as the SPIC method). The ILQ-NE increased the ILQ solubility ~1000 times more than its intrinsic solubility. It contained spherical droplets with a mean diameter of 44.10 ± 0.28 nm and a narrow size distribution. The ILQ loading capacity was 4%. The droplet size of ILQ-NE remained unchanged during storage at 4 °C for 56 days. Nanoemulsion encapsulation effectively prevented ILQ from degradation under ultraviolet light irradiation, and enhanced the ILQ in vitro release rate. In addition, ILQ-NE showed higher cellular uptake and superior cytotoxicity to 4T1 cancer cells compared with free ILQ formulations. In conclusion, ILQ-NE may facilitate the biomedical application of ILQ, and the SPIC method presents an attractive avenue for bridging the merits and eliminating the shortcomings of traditional high-energy methods and low-energy methods. Full article
Show Figures

Figure 1

14 pages, 2000 KiB  
Article
Adaptation of a Bacterial Bioluminescent Assay to Monitor Bioeffects of Gold Nanoparticles
by Moustafa R. Yehia, Tatyana E. Smolyarova, Alexandr V. Shabanov, Ekaterina S. Sushko, Gennady A. Badun and Nadezhda S. Kudryasheva
Bioengineering 2022, 9(2), 61; https://doi.org/10.3390/bioengineering9020061 - 03 Feb 2022
Cited by 5 | Viewed by 2537
Abstract
Our current study aimed to adapt a bioluminescent bacteria-based bioassay to monitor the bioeffects of gold nanoparticles (AuNPs). Luminous marine bacteria Photobacterium phosphoreum and AuNPs modified with polyvinylpyrrolidone were employed; low-concentration (≤10−3 g/L) bioeffects of AuNPs were studied. Bioluminescence intensity was used [...] Read more.
Our current study aimed to adapt a bioluminescent bacteria-based bioassay to monitor the bioeffects of gold nanoparticles (AuNPs). Luminous marine bacteria Photobacterium phosphoreum and AuNPs modified with polyvinylpyrrolidone were employed; low-concentration (≤10−3 g/L) bioeffects of AuNPs were studied. Bioluminescence intensity was used as an indicator of physiological activity in bacteria. Two additional methods were used: reactive oxygen species (ROS) content was estimated with a chemiluminescent luminol method, and bacterial size was monitored using electron microscopy. The bacterial bioluminescent response to AuNPs corresponded to the “hormesis” model and involved time-dependent bioluminescence activation, as well as a pronounced increase in the number of enlarged bacteria. We found negative correlations between the time courses of bioluminescence and the ROS content in bacterial suspensions, demonstrating the relationship between bioluminescence activation and bacterial ROS consumption. The combined effects of AuNPs and a beta-emitting radionuclide, tritium, revealed suppression of bacterial bioluminescent activity (as compared to their individual effects) and a reduced percentage of enlarged bacteria. Therefore, we demonstrated that our bacteria-based bioluminescence assay is an appropriate tool to study the bioeffects of AuNPs; the bioeffects can be further classified within a unified framework for rapid bioassessment. Full article
Show Figures

Figure 1

Back to TopTop